Immunogenicity of novel Dengue virus epitopes identified by bioinformatic analysis

Virus Research
Gilma Sánchez-BurgosEric Dumonteil

Abstract

We used T cell epitope prediction tools to identify epitopes from Dengue virus polyprotein sequences, and evaluated in vivo and in vitro the immunogenicity and antigenicity of the corresponding synthetic vaccine candidates. Twenty-two epitopes were predicted to have a high affinity for MHC class I (H-2Kd, H-2Dd, H-2Ld alleles) or class II (IAd alleles). These epitopes were conserved between the four virus serotypes, but with no similarity to human and mouse sequences. Thirteen synthetic peptides induced specific antibodies production with or without T cells activation in mice. Three synthetic peptides induced mostly IgG antibodies, and one of these from the E gene induced a neutralizing response. Ten peptides induced a combination of humoral and cellular responses by CD4+ and CD8+ T cells. Twelve peptides were novel B and T cell epitopes. These results indicate that our bioinformatics strategy is a powerful tool for the identification of novel antigens and its application to human HLA may lead to a potent epitope-based vaccine against Dengue virus and many other pathogens.

References

Jan 1, 1987·Transactions of the Royal Society of Tropical Medicine and Hygiene·J R BravoG P Kouri
May 1, 1993·Molecular Immunology·C LeclercV Deubel
Mar 22, 2002·Vaccine·Susana VázquezMayling Alvarez
Jan 23, 2004·Journal of Immunological Methods·Marlou M MangadaAlan L Rothman
Apr 2, 2004·The Journal of Clinical Investigation·Alan L Rothman
Jun 3, 2004·Genome Research·Gavin E CrooksSteven E Brenner
Jul 1, 2005·Protein Science : a Publication of the Protein Society·Pierre Dönnes, Oliver Kohlbacher
Aug 31, 2006·Current Opinion in Infectious Diseases·Sharone Green, Alan Rothman
Apr 17, 2007·Cellular Immunology·Asif M KhanJ Thomas August
Feb 12, 2009·Proteomics·Carla Herrera-NajeraEric Dumonteil

❮ Previous
Next ❯

Citations

Jun 21, 2011·Omics : a Journal of Integrative Biology·Fabio BagnoliRino Rappuoli
May 17, 2011·Current Opinion in Immunology·Ann L ObergGregory A Poland
Nov 26, 2010·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Shishir K GuptaShailendra K Gupta
Oct 2, 2014·Applied Biochemistry and Biotechnology·Mohamamd Mahdi RanjbarMaryam Taheri
Jul 30, 2014·The Journal of Infectious Diseases·Christian Teh-PootEric Dumonteil
Feb 23, 2018·Applied Microbiology and Biotechnology·Hossein FahimiMajid Sadeghizadeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.